Diastolic DysfunctionSepticHeartGNCT05552521
Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
An observational study of Diastolic Dysfunction and Septic Shock, run by Hospital Garcia de Orta at 1 site in Portugal.
Trial summary
Sepsis is a life-threatening infection with increasing incidence, and its spectrum of disease can involve cardiac dysfunction, which further adds to mortality. Although cardiac involvement in sepsis has been classically attributed to systolic dysfunction, diastolic dysfunction is increasingly diagnosed due to new… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diastolic Dysfunction, Septic Shock, Cardiomyopathies
- What is being tested?
- Echocardiography
- How many people
- 100 participants
- Where
- 1 sitePortugal
- Study dates
- 20 Sep 2022to 26 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A prospective multicenter observational study in the 30-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Who may be able to join
- All patients admitted in the ICU i. ≥ 18 years old; ii. with septic shock by the sepsis 3.0 criteria (13): Sepsis and (despite adequate volume resuscitation) both of: persistent hypotension requiring vasopressors to maintain MAP greater than or equal to 65 mm Hg, and lactate greater than or equal to 2 mmol/L.
Who cannot join
- pregnancy, congenital heart disease, artificial valve prosthesis, severe aortic or mitral pathology, atrial fibrillation, and inadequate image quality.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Early Diastolic Dysfunction in Patients With Septic Shock and Its Association With the Presence of Cardiomyopathy Genetic Variants
Sepsis is a life-threatening infection with increasing incidence, and its spectrum of disease can involve cardiac dysfunction, which further adds to mortality. Although cardiac involvement in sepsis has been classically attributed to systolic dysfunction, diastolic dysfunction is increasingly diagnosed due to new echocardiographic techniques and the conceptual evolution of diastolic dysfunction. Combining systolic and diastolic dysfunction assessment could lead to a better diagnosis of septic cardiac dysfunction. Furthermore, earlier forms of septic cardiac dysfunction could be more promptly recognized by measuring novel and less used parameters of diastolic dysfunction. We hypothesize that left atrium (LA) strain and isovolumetric relaxation time (IVRT) derived intervals could be new and earlier predictors of diastolic dysfunction in septic patients with a potential impact on clinical presentation and prognosis and that rare genetic variation associated with inherited cardiomyopathies could underline the risk and severity of sepsis-related myocardial dysfunction with potential impact on diagnosis and prognosis.
Read the detailed description
Primary outcome:
Presence of diastolic dysfunction at baseline or during evolution in patients presenting with septic shock and its impact on prognosis.
Secondary outcomes:
Development of heart failure symptoms and presence of myocardial dysfunction (either systolic or diastolic) at 30th day, 30-day mortality, mechanical ventilation duration, ICU length of stay, and hospital stay, and need for therapeutic change.
Mid-term prognosis will be assessed at six months follow-up for evaluation of the clinical functional class, LV systolic and diastolic function, and biomarkers.
METHODS AND TASK DESCRIPTION A prospective multicenter observational study in the 24-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Population :
- Inclusion: All patients admitted in the ICU i. ≥ 18 years old; ii. with septic shock by the sepsis 3.0 criteria: Sepsis and (despite adequate volume resuscitation) both of: persistent hypotension requiring vasopressors to maintain MAP greater than or equal to 65 mm Hg, and lactate greater than or equal to 2 mmol/L.
- Exclusion: pregnancy, congenital heart disease, artificial valve prosthesis, severe aortic or mitral pathology, atrial fibrillation, and inadequate image quality.
Study design summary A comprehensive echocardiogram is performed by an intensive care and echocardiography specialist at five-time points: the earliest opportunity following admission (< 24h); from 3rd to 5th day; from 7th to 10th day; 28th to 30th day or at ICU discharge, if before; and at 6-month (either in hospital or ambulatory) and at 28th day. Also, invasive arterial pressure and central venous pressure, and cardiac biomarkers (highly sensitive troponin T and NT-proBNP) will be measured in all the timepoints, and inflammatory biomarkers (adrenomedullin, IL-1 and 6) will be measured at baseline, between day 7 and 10, and at 28th day or discharge and at 6 months.
Echocardiography All echocardiographic measures are obtained with simultaneous ECG display, and the three different sets of measures are obtained with the patient in the same position. All Doppler measurements are averaged from three measurements in sinus rhythm.
In addition to the qualitative examination of chambers and valves, the following measurements are obtained via the standard parasternal and apical views:
- Pulmonary Artery Systolic Pressure: If the patient has tricuspid regurgitation, measured by continuous Doppler in Parasternal short axis, Parasternal view of right ventricular inflow tract or Apical four Chamber view.
- Left Atrium Measurements: Size, (M-Mode, 2D) Volume, in Apical 4 Chamber view and Apical 2 Chamber view).
- Left and Right Ventricle 2D Color and Doppler: LV end-diastolic and end-systolic volumes (EDV and ESV) using biplane modified Simpson's rule, from which EF is calculated; RV end-diastolic area ratio Fractional Area Change (FAC) of RV and Tricuspid Annular Plane Systolic Excursion (TAPSE); LVOT diameter, LVOT VTI measured on pulsed-wave Doppler from which SV is calculated. Then CO and CI derived at inspiration and expiration.
- Mitral Flow Measurements: E maximal velocity, A maximal velocity. 4-Chamber apical view, Pulsed Doppler, Average of 3 measurements in SR. Isovolumetric relaxation time, isovolumetric contraction time, and ejection time are measured on pulsed-wave Doppler in apical five-chamber, and care is taken to display distinct aortic valve closure and mitral valve opening signals simultaneously, and then MPI is derived, normalized to heart rate.
- Tissue Doppler Measurements: RV S wave, Septal e' and Lateral e' on four-chamber apical view. Average of 3 measurements in SR. The myocardial isovolumic relaxation time (IVRT') is measured from the end of systolic myocardial velocity during ejection (Sa) to onset of the early diastolic myocardial velocity (e') at the left lateral and septal mitral annulus, and the average is used; the time difference IVRT-IVRT' is further calculated to obtain the [IVRT-IVRT'] parameter. Myocardial Performance Index (MPI) is also calculated.
- Left Ventricular and Left Atrial strain: Images are analyzed offline using dedicated software. Global Longitudinal Strain is calculated as the average speckle tracking strain from each of the 18 LV segments from the 2, 4, and 3-chamber views. Peak strain value is derived from the maximal inflection point on the composite LA strain curve and grade based on recently published cutoffs. Calculations of LA functionality to assess conduit, reservoir, and booster function is performed using definitions from previous studies.
Tissue Doppler measurements are taken from the modal velocity, from septal and lateral mitral annulus.
Systolic dysfunction is defined as those with a calculated EF < 50%. Diastolic dysfunction is classified according to 2016 ASE/EACVI guidelines with a focused analysis on the simplified criteria as E/e' >15 and e' < 0.08 m/s.
Repeated measures for different echocardiographic parameters are taken by the same physician and by two different physicians to assess inter-and intra-observer variability.
Genetic analysis For genetic analysis, blood will be withdrawn from patients at ICU admission and sent to a certified laboratory for whole-exome sequencing, in collaboration with the Institute of Molecular Medicine (IMM).
Hemodynamic monitoring Continuous hemodynamic monitoring will be achieved by a bioimpedance device - Starling Baxter - in the first 72 hours, for registration of the following variables: indexed stroke volume, stroke volume variation, cardiac output, cardiac index, heart rate, dX/dt, ventricular ejection time, total fluid content (and the dynamic variation), total peripheral resistance index and cardiac power index.
Clinical data and biochemical biomarkers All demographic, clinical, hemodynamic, respiratory data, fluid balance, vasopressors, and lab results - including highly sensitive troponin T, NT-proBNP, adrenomedullin, IL-1, and 6 - are prospectively collected, as well as SOFA, SAPS-II, APACHE-II scores, and mortality until 30 days and 6-month of follow-up.
Statistics Continuous variables are expressed as mean ± standard deviation or median and interquartile range and compared between any two groups using t-test or the Mann-Whitney U test, as appropriate. The normality of distribution is evaluated by visual inspection of histograms and by the Kolmogorov Smirnov test. Categorical variables are expressed as proportions and compared with the Mantel- Haenszel Chi-square test or Fisher exact test.
A mathematical model (curve and surface fitting, and time series regression) will be created so that the LA strain rate and IVRT variables could be predictors of early diastolic dysfunction. Associations between rare genetic variants and the development of early and late cardiac dysfunction are tested.
- Conditions
- Diastolic Dysfunction, Septic Shock, Cardiomyopathies
- Being tested
- Echocardiography
- Medical subject headings
- Shock, Septic, Cardiomyopathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EchocardiographyDiagnostic test
Also called Genetic analysis
Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
What is being measured
The primary outcome is the main question the study is designed to answer.
Diastolic dysfunction
Left atrium strain in % and IVRTs intervals in msec
Measured: through study completion until 6 months
Hereditary Cardiomyopathy genetic variants
Search for cardiomyopathies genetic variantes that could explain a myocardial susceptibility to develop injury in septic shock
Measured: through study completion until 6 months
Secondary outcomes (2)
Heart failure
heart failure symptoms according to NYHA clarification at 30 days and 6 months
Measured: through study completion until 6 months
Mortality
Mortality at 30 days and 6 months
Measured: through study completion until 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2022
- Study start20 Sep 2022
- Primary completion26 Feb 2024
- Study completion26 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Diastolic DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Garcia de Orta
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto de Medicina Molecular João Lobo Antunes
- Responsible party
- Principal investigator, Filipe André Gonzalez, Hospital Garcia de Orta
- Investigators
- Filipe A Gonzalez, MD, PhD st., Principal investigator, Hospital Garcia de Orta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05552521
- Sponsor's protocol ID
- TI 01/2022
- Acronym
- SepticHeartG
- Status last verified
- Aug 2024
- First submitted
- 15 Sep 2022
- Last updated
- 9 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
PubMed 24638143Walley KR. Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018 Aug;24(4):292-299. doi: 10.1097/MCC.0000000000000507.
PubMed 29846206Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012 Apr;33(7):895-903. doi: 10.1093/eurheartj/ehr351. Epub 2011 Sep 11.
PubMed 21911341Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 May;34(19):1448-58. doi: 10.1093/eurheartj/ehs397. Epub 2012 Dec 4.
PubMed 23211230Gonzalez FA, Bacariza J, Varudo AR, Leote J, Mateus RM, Martins CM, Ribeiro MI, Sanfilippo F, Lopes LR, Almeida AG. Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis. Ann Intensive Care. 2025 Sep 25;15(1):141. doi: 10.1186/s13613-025-01561-w.
PubMed 40999250
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Diastolic Dysfunction in Patients With Septic Shock and Its Association With the Presence of Cardiomyopathy Genetic Variants
- ClinicalTrials.gov ID
- NCT05552521
- Acronym / sponsor ID
- SepticHeartG / TI 01/2022
- Conditions
- Diastolic Dysfunction, Septic Shock, Cardiomyopathies
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Hospital Garcia de OrtaUniversity, hospital or other
- Collaborators
- Instituto de Medicina Molecular João Lobo Antunes
- Study start
- 20 Sep 2022 (actual)
- Primary completion
- 26 Feb 2024 (actual)
- Study completion
- 26 Feb 2024 (actual)
- First posted
- 23 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is a life-threatening infection with increasing incidence, and its spectrum of disease can involve cardiac dysfunction, which further adds to mortality. Although cardiac involvement in sepsis has been classically attributed to systolic dysfunction, diastolic dysfunction is increasingly diagnosed due to new echocardiographic techniques and the conceptual evolution of diastolic dysfunction. Combining systolic and diastolic dysfunction assessment could lead to a better diagnosis of septic cardiac dysfunction. Furthermore, earlier forms of septic cardiac dysfunction could be more promptly recognized by measuring novel and less used parameters of diastolic dysfunction. We hypothesize that left atrium (LA) strain and isovolumetric relaxation time (IVRT) derived intervals could be new and earlier predictors of diastolic dysfunction in septic patients with a potential impact on clinical presentation and prognosis and that rare genetic variation associated with inherited cardiomyopathies could underline the risk and severity of sepsis-related myocardial dysfunction with potential impact on diagnosis and prognosis.
Detailed description
Primary outcome:
Presence of diastolic dysfunction at baseline or during evolution in patients presenting with septic shock and its impact on prognosis.
Secondary outcomes:
Development of heart failure symptoms and presence of myocardial dysfunction (either systolic or diastolic) at 30th day, 30-day mortality, mechanical ventilation duration, ICU length of stay, and hospital stay, and need for therapeutic change.
Mid-term prognosis will be assessed at six months follow-up for evaluation of the clinical functional class, LV systolic and diastolic function, and biomarkers.
METHODS AND TASK DESCRIPTION A prospective multicenter observational study in the 24-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Population :
- Inclusion: All patients admitted in the ICU i. ≥ 18 years old; ii. with septic shock by the sepsis 3.0 criteria: Sepsis and (despite adequate volume resuscitation) both of: persistent hypotension requiring vasopressors to maintain MAP greater than or equal to 65 mm Hg, and lactate greater than or equal to 2 mmol/L.
- Exclusion: pregnancy, congenital heart disease, artificial valve prosthesis, severe aortic or mitral pathology, atrial fibrillation, and inadequate image quality.
Study design summary A comprehensive echocardiogram is performed by an intensive care and echocardiography specialist at five-time points: the earliest opportunity following admission (< 24h); from 3rd to 5th day; from 7th to 10th day; 28th to 30th day or at ICU discharge, if before; and at 6-month (either in hospital or ambulatory) and at 28th day. Also, invasive arterial pressure and central venous pressure, and cardiac biomarkers (highly sensitive troponin T and NT-proBNP) will be measured in all the timepoints, and inflammatory biomarkers (adrenomedullin, IL-1 and 6) will be measured at baseline, between day 7 and 10, and at 28th day or discharge and at 6 months.
Echocardiography All echocardiographic measures are obtained with simultaneous ECG display, and the three different sets of measures are obtained with the patient in the same position. All Doppler measurements are averaged from three measurements in sinus rhythm.
In addition to the qualitative examination of chambers and valves, the following measurements are obtained via the standard parasternal and apical views:
- Pulmonary Artery Systolic Pressure: If the patient has tricuspid regurgitation, measured by continuous Doppler in Parasternal short axis, Parasternal view of right ventricular inflow tract or Apical four Chamber view.
- Left Atrium Measurements: Size, (M-Mode, 2D) Volume, in Apical 4 Chamber view and Apical 2 Chamber view).
- Left and Right Ventricle 2D Color and Doppler: LV end-diastolic and end-systolic volumes (EDV and ESV) using biplane modified Simpson's rule, from which EF is calculated; RV end-diastolic area ratio Fractional Area Change (FAC) of RV and Tricuspid Annular Plane Systolic Excursion (TAPSE); LVOT diameter, LVOT VTI measured on pulsed-wave Doppler from which SV is calculated. Then CO and CI derived at inspiration and expiration.
- Mitral Flow Measurements: E maximal velocity, A maximal velocity. 4-Chamber apical view, Pulsed Doppler, Average of 3 measurements in SR. Isovolumetric relaxation time, isovolumetric contraction time, and ejection time are measured on pulsed-wave Doppler in apical five-chamber, and care is taken to display distinct aortic valve closure and mitral valve opening signals simultaneously, and then MPI is derived, normalized to heart rate.
- Tissue Doppler Measurements: RV S wave, Septal e' and Lateral e' on four-chamber apical view. Average of 3 measurements in SR. The myocardial isovolumic relaxation time (IVRT') is measured from the end of systolic myocardial velocity during ejection (Sa) to onset of the early diastolic myocardial velocity (e') at the left lateral and septal mitral annulus, and the average is used; the time difference IVRT-IVRT' is further calculated to obtain the [IVRT-IVRT'] parameter. Myocardial Performance Index (MPI) is also calculated.
- Left Ventricular and Left Atrial strain: Images are analyzed offline using dedicated software. Global Longitudinal Strain is calculated as the average speckle tracking strain from each of the 18 LV segments from the 2, 4, and 3-chamber views. Peak strain value is derived from the maximal inflection point on the composite LA strain curve and grade based on recently published cutoffs. Calculations of LA functionality to assess conduit, reservoir, and booster function is performed using definitions from previous studies.
Tissue Doppler measurements are taken from the modal velocity, from septal and lateral mitral annulus.
Systolic dysfunction is defined as those with a calculated EF < 50%. Diastolic dysfunction is classified according to 2016 ASE/EACVI guidelines with a focused analysis on the simplified criteria as E/e' >15 and e' < 0.08 m/s.
Repeated measures for different echocardiographic parameters are taken by the same physician and by two different physicians to assess inter-and intra-observer variability.
Genetic analysis For genetic analysis, blood will be withdrawn from patients at ICU admission and sent to a certified laboratory for whole-exome sequencing, in collaboration with the Institute of Molecular Medicine (IMM).
Hemodynamic monitoring Continuous hemodynamic monitoring will be achieved by a bioimpedance device - Starling Baxter - in the first 72 hours, for registration of the following variables: indexed stroke volume, stroke volume variation, cardiac output, cardiac index, heart rate, dX/dt, ventricular ejection time, total fluid content (and the dynamic variation), total peripheral resistance index and cardiac power index.
Clinical data and biochemical biomarkers All demographic, clinical, hemodynamic, respiratory data, fluid balance, vasopressors, and lab results - including highly sensitive troponin T, NT-proBNP, adrenomedullin, IL-1, and 6 - are prospectively collected, as well as SOFA, SAPS-II, APACHE-II scores, and mortality until 30 days and 6-month of follow-up.
Statistics Continuous variables are expressed as mean ± standard deviation or median and interquartile range and compared between any two groups using t-test or the Mann-Whitney U test, as appropriate. The normality of distribution is evaluated by visual inspection of histograms and by the Kolmogorov Smirnov test. Categorical variables are expressed as proportions and compared with the Mantel- Haenszel Chi-square test or Fisher exact test.
A mathematical model (curve and surface fitting, and time series regression) will be created so that the LA strain rate and IVRT variables could be predictors of early diastolic dysfunction. Associations between rare genetic variants and the development of early and late cardiac dysfunction are tested.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A prospective multicenter observational study in the 30-bed polyvalent ICU of Hospital Garcia de Orta, Almada, Portugal. Expected sample size of 140 patients, to have a confidence level of 95%, with a precision within ± 5% (population of septic patients in the ICU/yearly).
Key inclusion criteria (1 listed)
- All patients admitted in the ICU i. ≥ 18 years old; ii. with septic shock by the sepsis 3.0 criteria (13): Sepsis and (despite adequate volume resuscitation) both of: persistent hypotension requiring vasopressors to maintain MAP greater than or equal to 65 mm Hg, and lactate greater than or equal to 2 mmol/L.
Key exclusion criteria (1 listed)
- pregnancy, congenital heart disease, artificial valve prosthesis, severe aortic or mitral pathology, atrial fibrillation, and inadequate image quality.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EchocardiographyAlso: Genetic analysisEchocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission | Diagnostic test | – |
Primary outcome
Diastolic dysfunction
Time frame: through study completion until 6 months
Left atrium strain in % and IVRTs intervals in msec
Hereditary Cardiomyopathy genetic variants
Time frame: through study completion until 6 months
Search for cardiomyopathies genetic variantes that could explain a myocardial susceptibility to develop injury in septic shock
2 secondary outcomes
Heart failure
Time frame: through study completion until 6 months
Mortality
Time frame: through study completion until 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2024.
- Background: PubMed 24638143Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
- Background: PubMed 29846206Walley KR. Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018 Aug;24(4):292-299. doi: 10.1097/MCC.0000000000000507.
- Background: PubMed 21911341Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, Avidan A, Beeri R, Weissman C, Jaffe AS, Sprung CL. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012 Apr;33(7):895-903. doi: 10.1093/eurheartj/ehr351. Epub 2011 Sep 11.
- Background: PubMed 23211230Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 May;34(19):1448-58. doi: 10.1093/eurheartj/ehs397. Epub 2012 Dec 4.
- Derived from this study: PubMed 40999250Gonzalez FA, Bacariza J, Varudo AR, Leote J, Mateus RM, Martins CM, Ribeiro MI, Sanfilippo F, Lopes LR, Almeida AG. Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis. Ann Intensive Care. 2025 Sep 25;15(1):141. doi: 10.1186/s13613-025-01561-w.
- Individual participant dataSharing planned: No
Related trials for Diastolic Dysfunction
Not yet recruiting
Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)
Valvular Heart Disease Patients, Aortic Stenosis
Recruiting
Optimised Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease
Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF)
Not yet recruitingObservational study
Changes in Intramyocardial Fat Assessed by Cardiac CT Before and After Bariatric Surgery and Their Relationship With Cardiac Diastolic Function
Obesity, Diastolic Dysfunction
Active, not recruitingObservational study
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study
HIV Infections
Not yet recruiting
Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive Patients
Hypertension, Left Ventricular Diastolic Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Filipe A Gonzalez, MD, PhD st. principal investigator
Hospital Garcia de Orta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diastolic Dysfunction and Septic Shock, run by Hospital Garcia de Orta at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diastolic dysfunction (time frame: through study completion until 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05552521, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2024.